

CORRECTION

Open Access




Correction: Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study

Maggie McCue^{1*}, Sara Sarkey¹, Anna Eramo², Clement François² and Sagar V. Parikh³

Abstract

Graphical Abstract

Using the Goal Attainment Scale Adapted for Depression (GAS-D) to Better Understand Treatment Outcomes in Patients With Major Depressive Disorder (MDD) Switching to Vortioxetine: A Phase 4, Single-Arm, Open-Label, Multicenter Study



The original article can be found online at <https://doi.org/10.1186/s12888-021-03608-1>.

*Correspondence: Maggie.McCue@takeda.com

¹Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA 02421, USA

Full list of author information is available at the end of the article



© The Author(s) 2022. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Correction to: BMC Psychiatry 21, 622 (2021)
<https://doi.org/10.1186/s12888-021-03608-1>

Following the publication of the original article [1], the authors would like to add the graphical abstract. The previous amendment can be found on <https://doi.org/10.1186/s12888-022-03798-2>.

The original article [1] has been corrected.

Author details

¹Takeda Pharmaceuticals U.S.A., Inc., 95 Hayden Avenue, Lexington, MA 02421, USA. ²Lundbeck LLC, 6 Parkway North Blvd, Deerfield, IL 60015, USA. ³University of Michigan Health, 1500 E. Medical Center Dr, Ann Arbor, MI 48109, USA.

Published online: 08 June 2022

Reference

1. McCue, et al. Using the Goal Attainment Scale adapted for depression to better understand treatment outcomes in patients with major depressive disorder switching to vortioxetine: a phase 4, single-arm, open-label, multicenter study. *BMC Psychiatry*. 2021;21:622. <https://doi.org/10.1186/s12888-021-03608-1>.